Advertisement
DXCM vs NVST
Which Stock Would AI Choose? DexCom (DXCM) vs. Envista Holdings (NVST) Stock Comparison
Key Takeaways
- DXCM is delivering double-digit revenue growth, expanding margins, and newly validated clinical data, while NVST is executing a steadier earnings recovery against persistent macro headwinds.
- The two companies operate in different corners of healthcare — DexCom in continuous glucose monitoring (CGM), and Envista in dental products and technologies — making this a study in contrasting growth profiles and risk exposures.
- DXCM has outperformed through 2026, gaining roughly 25% year-to-date on strong U.S. demand and the G7 15 Day rollout, while NVST has shown more modest momentum with a smaller market capitalization.
- Tickeron AI Verdict: Between the two, Tickeron's AI currently favors DXCM, based on stronger trend consistency, cleaner catalysts, and more stable relative positioning.
- For more context on each name, explore the DXCM Major News and DXCM Today's Price Move pages, as well as NVST Major News and NVST Today's Price Move.
- To see how AI-driven strategies are navigating names like these, explore Trending AI Robots.
Introduction
DexCom and Envista Holdings are both healthcare-focused manufacturers, yet they sit at opposite ends of the sector's growth and risk spectrum. DexCom designs continuous glucose monitoring systems for people with diabetes, a market enjoying secular expansion driven by broader reimbursement and clinical validation. Envista supplies dental implants, orthodontics, and digital imaging, a business more sensitive to elective procedure volumes and macroeconomic cycles. This stock comparison is relevant for investors weighing a higher-growth, higher-multiple med-tech franchise against a value-oriented turnaround with clear catalysts but tangible policy and tariff risks. Understanding their relative performance and market positioning can help clarify which profile better suits a given portfolio.
DXCM Overview and Recent Performance
DXCM, or DexCom, is a medical device leader in continuous glucose monitoring, or CGM, technology used by people with diabetes to track blood sugar in real time. The company has posted strong results in recent quarters, with third-quarter revenue rising about 11% year over year to roughly $1.34 billion, led by 14% U.S. growth. Adjusted gross margin expanded meaningfully, and management raised its full-year revenue outlook, reflecting confidence in sustained demand.
Recent market activity has been shaped by several positive catalysts. The publication of the CONNECT study in the New England Journal of Medicine strengthened the clinical case for CGM use among people with type 2 diabetes not taking insulin, which investors view as a potential driver of expanded Medicare and commercial coverage. The ongoing rollout of the G7 15 Day extended-wear sensor, a new share repurchase authorization, and progress toward direct distribution in Europe have further supported sentiment. The stock has gained roughly 25% year-to-date, outperforming the broader healthcare sector.
NVST Overview and Recent Performance
NVST, or Envista Holdings, develops and markets dental products including the Nobel Biocare implant portfolio, Spark clear aligners, and DEXIS digital imaging systems. The company is navigating a turnaround supported by improving profitability, with third-quarter revenue of approximately $691.5 million and adjusted earnings per share (EPS) that beat analyst estimates. Management raised its full-year adjusted EPS guidance, signaling confidence in operational execution.
Envista's recent performance reflects both progress and headwinds. Core sales have grown in the mid-single digits, with strength in consumables and diagnostics, while elective categories such as orthodontics and implants have lagged historical levels. Ongoing uncertainty around China's volume-based procurement (VBP) program for medical devices, tariff costs, and foreign-exchange exposure have weighed on sentiment, and the stock has traded more cautiously than its larger med-tech peers. These dynamics make NVST a more execution-dependent story in the current environment.
Trending AI Robots
Tickeron's Trending AI Robots page curates a focused selection from a much larger universe of AI trading bots that collectively monitor thousands of tickers. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the specific sets of tickers they trade, with many generating dozens or more active signals. Only the bots best suited to prevailing market conditions are featured in the Trending section, giving users a filtered view of strategies currently demonstrating the strongest fit. For investors comparing names like DXCM and NVST, this page offers a way to observe how quantitative, rules-based approaches are positioning in real time. Browsing the curated Trending AI Robots can provide additional context on how AI-driven strategies are adapting to shifting market conditions.
Head-to-Head Comparison
The contrast between these two names is sharp. DexCom benefits from a large, growing addressable market in diabetes care, recurring sensor revenue, and a powerful clinical catalyst in the form of potential reimbursement expansion. Its trade-off is valuation: shares command a premium multiple that leaves less room for execution missteps. Envista, by contrast, trades at a lower absolute valuation and is rebuilding margins through productivity gains and new product launches, but it faces China VBP pricing pressure, tariff costs, and exposure to elective dental demand.
In terms of momentum, DXCM's trend has been more consistent through 2026, supported by positive earnings revisions and product-cycle strength. NVST's recovery is real but more uneven, with analyst ratings generally positive yet tempered by macro uncertainty. Sector exposure also differs: DexCom is tied to medical device reimbursement and diabetes prevalence, while Envista is more cyclical and geographically diversified, with over half of revenue generated outside the United States. Risk profiles diverge accordingly, with DXCM concentrated around reimbursement and competition, and NVST concentrated around policy, tariffs, and procedure volumes.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor DXCM in the current environment. The stock combines more consistent trend strength, accelerating margin expansion, and clearly defined catalysts in the form of clinical validation and potential coverage expansion. While NVST offers an improving earnings trajectory and a lower valuation, its forward path is more heavily dependent on resolving China pricing uncertainty and managing tariff headwinds. On balance, the AI's probabilistic assessment tilts toward DexCom for its steadier momentum and more favorable relative positioning, though this reflects a data-driven view of current conditions rather than a definitive forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DXCM is a Buy and NVST is a Hold.
DXCM saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for DXCM moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 62 similar instances where the indicator exited the overbought zone. In 48 of the 62 cases the stock moved lower. This puts the odds of a downward move at 77%.
Technical Analysis (Indicators)
Bearish Trend Analysis
DXCM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXCM crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for DXCM entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DXCM's RSI Indicator exited the oversold zone, 22 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on DXCM as a result. In 62 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for DXCM just turned positive on November 02, 2026. Looking at past instances where DXCM's MACD turned positive, the stock continued to rise in 31 of 45 cases over the following month. The odds of a continued upward trend are 69%.
Following a +6.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 199 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.431) is normal, around the industry mean (4.142). P/E Ratio (30.779) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NVST's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for NVST turned positive on October 06, 2026. Looking at past instances where NVST's MACD turned positive, the stock continued to rise in 35 of 49 cases over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on NVST as a result. In 71 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
NVST moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NVST crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +10.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVST advanced for three days, in 171 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVST moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 15 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 63 cases where NVST's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
NVST broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NVST entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. NVST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.314) is normal, around the industry mean (4.964). P/E Ratio (42.661) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.451) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DXCM | NVST | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 64 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 27 | 87 | |
PRICE GROWTH RATING 1..100 | 45 | 46 | |
P/E GROWTH RATING 1..100 | 53 | 96 | |
SEASONALITY SCORE 1..100 | 5 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVST's Valuation (64) in the null industry is in the same range as DXCM (83) in the Medical Specialties industry. This means that NVST’s stock grew similarly to DXCM’s over the last 12 months.
NVST's Profit vs Risk Rating (100) in the null industry is in the same range as DXCM (100) in the Medical Specialties industry. This means that NVST’s stock grew similarly to DXCM’s over the last 12 months.
DXCM's SMR Rating (27) in the Medical Specialties industry is somewhat better than the same rating for NVST (87) in the null industry. This means that DXCM’s stock grew somewhat faster than NVST’s over the last 12 months.
DXCM's Price Growth Rating (45) in the Medical Specialties industry is in the same range as NVST (46) in the null industry. This means that DXCM’s stock grew similarly to NVST’s over the last 12 months.
DXCM's P/E Growth Rating (53) in the Medical Specialties industry is somewhat better than the same rating for NVST (96) in the null industry. This means that DXCM’s stock grew somewhat faster than NVST’s over the last 12 months.
| DXCM | NVST | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 63% | 3 days ago 68% |
| Stochastic ODDS (%) | 3 days ago 77% | 3 days ago 75% |
| Momentum ODDS (%) | 3 days ago 70% | 3 days ago 66% |
| MACD ODDS (%) | 3 days ago 69% | 4 days ago 71% |
| TrendWeek ODDS (%) | 3 days ago 72% | 3 days ago 67% |
| TrendMonth ODDS (%) | 3 days ago 75% | 3 days ago 69% |
| Advances ODDS (%) | 7 days ago 67% | 5 days ago 64% |
| Declines ODDS (%) | 3 days ago 74% | 21 days ago 70% |
| BollingerBands ODDS (%) | 3 days ago 64% | 3 days ago 73% |
| Aroon ODDS (%) | 3 days ago 71% | 3 days ago 74% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DXCM’s FA Score shows that 1 FA rating(s) are green while NVST’s FA Score has 0 green FA rating(s).
- DXCM’s FA Score: 1 green, 4 red.
- NVST’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DXCM’s TA Score shows that 5 TA indicator(s) are bullish while NVST’s TA Score has 5 bullish TA indicator(s).
- DXCM’s TA Score: 5 bullish, 5 bearish.
- NVST’s TA Score: 5 bullish, 5 bearish.
Price Growth
DXCM (@Medical/Nursing Services) experienced а -3.50% price change this week, while NVST (@Pharmaceuticals: Other) price change was +7.06% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.27%. For the same industry, the average monthly price growth was -8.05%, and the average quarterly price growth was -7.48%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.17%. For the same industry, the average monthly price growth was +1.17%, and the average quarterly price growth was +12.16%.
Reported Earning Dates
DXCM is expected to report earnings on Feb 11, 2027.
NVST is expected to report earnings on Feb 10, 2027.
Industries' Descriptions
@Medical/Nursing Services (-3.27% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+2.17% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
DXCM and
Correlation & Price change
A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with ISRG. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To DXCM | 1D Price Change % | ||
|---|---|---|---|---|
| DXCM | 100% | -5.98% | ||
| ISRG - DXCM | 46% Loosely correlated | -3.36% | ||
| ALGN - DXCM | 44% Loosely correlated | +4.16% | ||
| LIVN - DXCM | 42% Loosely correlated | -1.26% | ||
| PODD - DXCM | 41% Loosely correlated | -6.16% | ||
| NVST - DXCM | 40% Loosely correlated | +0.84% | ||
More | ||||
NVST and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVST has been closely correlated with ALGN. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVST jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To NVST | 1D Price Change % | ||
|---|---|---|---|---|
| NVST | 100% | +0.84% | ||
| ALGN - NVST | 70% Closely correlated | +4.16% | ||
| XRAY - NVST | 63% Loosely correlated | -6.24% | ||
| BIO - NVST | 57% Loosely correlated | +3.41% | ||
| A - NVST | 55% Loosely correlated | +1.73% | ||
| MTD - NVST | 52% Loosely correlated | +2.57% | ||
More | ||||